Zenas BioPharma, Inc.
NMS: ZBIOLive Quote
📈 ZcoreAI Score
Our AI model analyzes Zenas BioPharma, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ZBIO Z-Score →About Zenas BioPharma, Inc.
Healthcare
Biotechnology
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
📊 Fundamental Analysis
Zenas BioPharma, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -100.0% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -136.2%, which indicates that capital utilization is currently under pressure.
At a current price of $20.44, ZBIO currently sits at the 35th percentile of its 52-week range (Range: $7.34 - $44.60).
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Debt/Equity
Moderate
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
Key Financials
Market Cap
$1.27B
Trailing P/E
--
Forward P/E
-4.23
Beta (5Y)
--
52W High
$44.60
52W Low
$7.34
Avg Volume
820K
Day High
Day Low